Alerts
-
The head of Hong Kong’s new drug regulatory body has pledged to build a fully capable and globally trusted agency that will become a catalyst for medical innovation rather than merely acting as a “miniature version” of existing overseas models. Dr Li Zili, controller of the Hong Kong Centre for Medical Products Regulation (CMPR), said that while many other places in Asia, such as mainland China, Singapore and Japan, had established regulatory agencies long ago, Hong Kong had a distinctive...
Comment